Immunovant (IMVT) Profit After Tax (2018 - 2026)

Immunovant (IMVT) has 9 years of Profit After Tax data on file, last reported at -$147.9 million in Q1 2026.

• Quarterly Profit After Tax fell 38.9% year-over-year to -$147.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$505.6 million (down 22.17% YoY) and the FY2026 annual result came in at -$505.6 million, down 22.17% from the prior year.
• Profit After Tax eased to -$147.9 million in Q1 2026, from -$110.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$40.4 million in Q2 2022 to a low of -$147.9 million in Q1 2026.
• A 5-year average of -$84.5 million and a median of -$75.3 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax climbed 18.68% — and 2024, when it plunged 116.11%.
• Tracing IMVT's Profit After Tax over 5 years: stood at -$63.2 million in 2022, then advanced by 18.68% to -$51.4 million in 2023, then sank by 116.11% to -$111.1 million in 2024, then advanced by 0.44% to -$110.6 million in 2025, then tumbled by 33.64% to -$147.9 million in 2026.
• The last three Profit After Tax figures came in at -$147.9 million (Q1 2026), -$110.6 million (Q4 2025), and -$126.5 million (Q3 2025), per Business Quant data.